Indivior Pharmaceuticals, Inc 6-K, filed Nov 17, 2023
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2023-11-17
For: 2023-11-17
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on November 17, 2023.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: November 17, 2023
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
|
|
99.2
|
|
|
99.3
|
|
|
99.4
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: November 17,
2023
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
November 17, 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF
ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS
PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018).
Indivior Amends its Relationship Agreement with Scopia Capital
Management
Indivior PLC (the "Company") (LSE/Nasdaq: INDV) announced that it
has amended the existing relationship agreement (the "Relationship
Agreement") with Scopia Capital Management LP ("Scopia") which will
extend Mr Jerome Lande's Board tenure until December 31,
2024.
Scopia is a valued longstanding shareholder of the Company and,
having considered the positive contributions Mr Lande has made as
Scopia's Representative Director and the continued shareholder
perspective and capital markets experience he brings, the Board
believe his ongoing service will continue to benefit the Company
and serve all shareholders' best interests.
In the light of these considerations and the benefits to the
Company from the continuation of certain terms of the Relationship
Agreement, the Company and Scopia have agreed to extend the term of
the Relationship Agreement for a further year i.e. until December
31, 2024, unless it is otherwise extended by mutual agreement or
terminated at an earlier date in accordance with its terms. The
threshold for automatic termination will be amended, such that the
Relationship Agreement will terminate in the event that Scopia (and
its affiliates) cease to have interests in at least 3% of the
Company's issued share capital (reduced from 5%).
The other provisions of the original Relationship Agreement will
remain in full force and effect, including certain customary
standstill, voting and governance provisions appropriate for an
agreement between a premium listed company and a significant
shareholder. This includes commitments from Scopia (applicable to
it and its affiliates) to:
●
Not
exercise any voting rights in excess of 15% of the voting rights
exercisable in the Company from time-to-time;
●
Exercise
its voting rights in relation to ordinary course resolutions in
accordance with the recommendation of the Board; and
●
Not
exercise its shareholder rights in a manner inconsistent with the
Board's recommendation (other than in respect of certain
non-ordinary course resolutions).
The person responsible for making this announcement is Kathryn
Hudson, Company Secretary.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United States in
Richmond, VA, Indivior employs more than 1,000 individuals globally
and its portfolio of products is available in 37 countries
worldwide. Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
For Further Information
|
Jason Thompson
|
VP, Investor Relations
Indivior PLC
|
+1 804 402 7123
jason.thompson@indivior.com
|
|
Tim Owens
|
Director, Investor Relations Indivior PLC
|
+1 804 263 3978
timothy.owens@indivior.com
|
Important Cautionary Note Regarding Forward-Looking
Statements
This announcement contains certain statements that are
forward-looking, including "forward-looking" statements made within
the meaning of Section 21E of the United States Securities Exchange
Act of 1934. Forward-looking statements include, among other
things, statements regarding the Indivior Group's financial
guidance for 2023 and its medium- and long-term growth outlook;
strategies for value creation and operational goals; expectations
for sales levels for particular products; expected market growth
rates, growing normalization of medically assisted treatment for
opioid use disorder, and expanded access to treatment; expected
changes in market share; future exchange rates; our product
development pipeline and potential future products, expectations
regarding regulatory approval of such product candidates, the
timing of such approvals, and the timing of commercial launch of
such products or product candidates, and eventual annual revenues
of such future products; expectations regarding the extent and
impact of competition; and other statements containing the words
"believe", "anticipate", "plan", "expect", "intend", "estimate",
"forecast," "strategy," "target," "guidance," "outlook,"
"potential", "project", "priority," "may", "will", "should",
"would", "could", "can", "outlook," "guidance", the negatives
thereof, and variations thereon and similar expressions. By their
nature, forward-looking statements involve risks and uncertainties
as they relate to events or circumstances that may or may not occur
in the future.
Actual results may differ materially from those expressed or
implied in such statements because they relate to future events.
Various factors may cause differences between Indivior's
expectations and actual results, including, among others, the
substantial litigation and ongoing investigations to which we are
or may become a party; our reliance on third parties to manufacture
commercial supplies of most of our products, conduct our clinical
trials and at times to collaborate on products in our pipeline; our
ability to comply with legal and regulatory settlements, healthcare
laws and regulations, requirements imposed by regulatory agencies
and payment and reporting obligations under government pricing
programs; risks related to the manufacture and distribution of our
products, some of which are controlled substances; market
acceptance of our products as well as our ability to commercialize
our products and compete with other market participants; the
uncertainties related to the development of new products, including
through acquisitions, and the related regulatory approval process;
our dependence on a small number of significant customers; our
ability to retain key personnel or attract new personnel; our
dependence on third-party payors for the reimbursement of our
products and the increasing focus on pricing and competition in our
industry; unintended side effects caused by the clinical study or
commercial use of our products; our use of hazardous materials in
our manufacturing facilities; our import, manufacturing and
distribution of controlled substances; our ability to successfully
execute acquisitions, partnerships, joint ventures, dispositions or
other strategic acquisitions; our ability to protect our
intellectual property rights and the substantial cost of litigation
or other proceedings related to intellectual property rights; the
risks related to product liability claims or product recalls; the
significant amount of laws and regulations that we are subject to,
including due to the international nature of our business;
macroeconomic trends and other global developments; the terms of
our debt instruments, changes in our credit ratings and our ability
to service our indebtedness and other obligations as they come due;
changes in applicable tax rate or tax rules, regulations or
interpretations; our ability to realize our deferred tax assets;
and changes in our market position, businesses, financial
condition, results of operations or prospects. Additional
information concerning these and other factors can be found in
Indivior PLC's filings with the United States Securities and
Exchange Commission ("SEC"), including Indivior PLC's registration
statement on Form 20-F, which was declared effective by the SEC on
June 9, 2023, and Current Reports on Form 6-K, which may be
obtained free of charge at the SEC's website, http://www.sec.gov,
and Indivior PLC's Annual Reports, which may be obtained free of
charge from Indivior PLC's website,
https://www.indivior.com/.
Forward-looking statements speak only as of the date that they are
made and should be regarded solely as our current plans, estimates
and beliefs. Except as required by law, we do not undertake and
specifically decline any obligation to update, republish or revise
forward-looking statements to reflect future events or
circumstances or to reflect the occurrences of unanticipated
events. Readers
are cautioned not to place undue reliance on any such
forward-looking statements.
-ends-
Exhibit
99.2
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
|
GB00BN4HT335
|
Issuer Name
|
INDIVIOR PLC
|
UK or Non-UK Issuer
|
UK
|
2. Reason for Notification
|
An acquisition or disposal of voting rights
|
3. Details of person subject to the notification
obligation
Name
|
Madison Avenue Partners LP
|
City of registered office (if applicable)
|
New York
|
Country of registered office (if applicable)
|
United States
|
4. Details of the shareholder
|
Name
|
City
of registered office
|
Country
of registered office
|
|
Madison
Avenue International LP
|
New
York
|
United
States
|
5. Date on which the threshold was crossed or reached
|
14-Nov-2023
|
6. Date on which Issuer notified
|
16-Nov-2023
|
7. Total positions of person(s) subject to the notification
obligation
|
|
% of voting rights attached to shares (total of 8.A)
|
% of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer
|
|
Resulting
situation on the date on which threshold was crossed or
reached
|
3.353376
|
0.000000
|
3.353376
|
4625619
|
|
Position
of previous notification (if applicable)
|
|
|
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
|
GB00BN4HT335
|
4625619
|
|
3.353376
|
|
|
Sub
Total 8.A
|
4625619
|
3.353376%
|
||
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
|
8B2. Financial Instruments with similar economic effect according
to (DTR5.3.1R.(1) (b))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
Swap
|
24/5/2029
|
N/A
|
Cash
|
0
|
0.000000
|
|
Sub
Total 8.B2
|
|
0
|
0.000000%
|
||
9. Information in relation to the person subject to the
notification obligation
|
2. Full chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held
starting with the ultimate controlling natural person or legal
entities (please add additional rows as necessary)
|
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
Eli
Samaha
|
Madison
Avenue Partners LP
|
3.353376
|
0.000000
|
3.353376%
|
10. In case of proxy voting
Name of the proxy holder
|
|
The number and % of voting rights held
|
|
The date until which the voting rights will be held
|
|
11. Additional Information
|
|
12. Date of Completion
|
16-Nov-2023
|
13. Place Of Completion
|
New York
|
Exhibit
99.3
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
|
GB00BN4HT335
|
Issuer Name
|
INDIVIOR PLC
|
UK or Non-UK Issuer
|
UK
|
2. Reason for Notification
|
An acquisition or disposal of financial instruments
|
3. Details of person subject to the notification
obligation
Name
|
The Goldman Sachs Group, Inc.
|
City of registered office (if applicable)
|
Wilmington, Delaware
|
Country of registered office (if applicable)
|
USA
|
4. Details of the shareholder
|
Name
|
City
of registered office
|
Country
of registered office
|
|
Goldman
Sachs International
|
London
|
United
Kingdom
|
5. Date on which the threshold was crossed or reached
|
14-Nov-2023
|
6. Date on which Issuer notified
|
16-Nov-2023
|
7. Total positions of person(s) subject to the notification
obligation
|
|
% of voting rights attached to shares (total of 8.A)
|
% of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer
|
|
Resulting
situation on the date on which threshold was crossed or
reached
|
0.150099
|
4.998967
|
5.149066
|
7102581
|
|
Position
of previous notification (if applicable)
|
0.042726
|
5.022807
|
5.065533
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
|
GB00BN4HT335
|
|
207046
|
|
0.150099
|
|
Sub
Total 8.A
|
207046
|
0.150099%
|
||
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
Securities
Lending
|
Open
|
|
6413639
|
4.649614
|
|
Sub
Total 8.B1
|
|
6413639
|
4.649614%
|
|
8B2. Financial Instruments with similar economic effect according
to (DTR5.3.1R.(1) (b))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
Swap
|
05-Sep-2033
|
|
Cash
|
249929
|
0.181188
|
|
Swap
|
28-Feb-2033
|
|
Cash
|
84481
|
0.061245
|
|
Swap
|
10-Nov-2033
|
|
Cash
|
72897
|
0.052847
|
|
Swap
|
23-May-2033
|
|
Cash
|
22558
|
0.016353
|
|
Swap
|
10-Oct-2033
|
|
Cash
|
18211
|
0.013202
|
|
Swap
|
16-May-2033
|
|
Cash
|
16129
|
0.011693
|
|
Swap
|
16-Nov-2026
|
|
Cash
|
6800
|
0.004930
|
|
Swap
|
15-Nov-2027
|
|
Cash
|
3343
|
0.002423
|
|
Swap
|
25-Oct-2033
|
|
Cash
|
2155
|
0.001563
|
|
Swap
|
14-Nov-2033
|
|
Cash
|
2094
|
0.001518
|
|
Swap
|
22-Sep-2033
|
|
Cash
|
1656
|
0.001200
|
|
Swap
|
28-Feb-2033
|
|
Cash
|
1161
|
0.000841
|
|
Swap
|
29-Jan-2030
|
|
Cash
|
231
|
0.000167
|
|
Swap
|
14-Nov-2033
|
|
Cash
|
179
|
0.000130
|
|
Swap
|
26-Oct-2026
|
|
Cash
|
56
|
0.000041
|
|
Swap
|
14-Nov-2033
|
|
Cash
|
16
|
0.000012
|
|
Sub
Total 8.B2
|
|
481896
|
0.349353%
|
||
9. Information in relation to the person subject to the
notification obligation
|
2. Full chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held
starting with the ultimate controlling natural person or legal
entities (please add additional rows as necessary)
|
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
The
Goldman Sachs Group, Inc. (Chain 1)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 1)
|
Goldman
Sachs (UK) L.L.C.
|
0.108136
|
4.990824
|
5.098960%
|
|
The
Goldman Sachs Group, Inc. (Chain 1)
|
Goldman
Sachs Group UK Limited
|
0.108136
|
4.990824
|
5.098960%
|
|
The
Goldman Sachs Group, Inc. (Chain 1)
|
Goldman
Sachs International
|
0.108136
|
4.990824
|
5.098960%
|
|
The
Goldman Sachs Group, Inc. (Chain 2)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 2)
|
GSAM
Holdings LLC
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 2)
|
Goldman
Sachs Asset Management, L.P.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 3)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 3)
|
Folio
Financial, Inc.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 3)
|
Folio
Investments Inc.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 4)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 4)
|
The
Goldman Sachs Group, Inc.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 4)
|
Goldman
Sachs Bank USA
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 4)
|
Goldman
Sachs Bank Europe SE
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 5)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 5)
|
Goldman
Sachs & Co. LLC
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
|
|
The number and % of voting rights held
|
|
The date until which the voting rights will be held
|
|
11. Additional Information
|
Please note, the total amount of voting rights have been rounded to
6 decimal places therefore there is a possibility of a rounding
error. General email contact: gs-regops-emea-position-enquiries@gs.com
|
12. Date of Completion
|
16-Nov-2023
|
13. Place Of Completion
|
Warsaw
|
Exhibit 99.4
FOR IMMEDIATE RELEASE
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF
ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS
PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018).
Indivior Announces $100 Million Share Repurchase
Program
Richmond, VA, November 17, 2023 - Indivior PLC (LSE/Nasdaq: INDV) ("Indivior" or the
"Company"), a leading addiction
treatment company, today announced that its Board of Directors has authorized a new
share repurchase program under which the Company will commence
repurchasing Indivior's ordinary shares of $0.50 each (the
"Ordinary Shares") for up to a maximum consideration of $100
million (the "Program").
"Given our confidence in delivering on the medium-term profitable
growth profile we outlined at our capital markets day last
December, the Board of Directors and management team believe that
the Company's shares represent an attractive investment
opportunity," said Mark Crossley, Chief Executive Officer. "Our
expected strong cash flow over this period provides us the ability
to reinvest in our business, progress our pipeline, and to take
this action to deliver direct shareholder returns."
Indivior has entered into an irrevocable, non-discretionary
agreement with Morgan Stanley & Co. International Plc ("Morgan
Stanley") in relation to the Program and for Morgan Stanley to
carry out on-market purchases of Ordinary Shares, acting as
riskless principal, during the period commencing on November 20,
2023, and ending no later than August 30, 2024, for an aggregate
purchase price of no greater than $100 million and the simultaneous
on-sale of such Ordinary Shares by Morgan Stanley to
Indivior.
Morgan Stanley will make trading decisions in relation to the
Program independently of Indivior in accordance with certain
pre-set parameters set out in the agreement with Morgan Stanley.
Any purchases of Ordinary Shares under the Program will be carried
out on the London Stock Exchange and/or on Aquis Stock Exchange
and/or on CBOE Europe Limited, being Multilateral Trading
Facilities as defined by the Directive 2014/65/EU on markets in
financial instruments (including the delegated and implementing
acts adopted under it) as implemented, retained, amended, extended,
re-enacted or otherwise given effect in the United Kingdom from
January 1, 2021 and as amended or supplemented in the United
Kingdom thereafter, and executed in accordance with Chapter 12 of
the Financial Conduct Authority's Listing Rules and Indivior's
general authority to make market purchases of Ordinary Shares
granted by its shareholders at the annual general meeting held on
May 4, 2023 (the "Authority"). The Ordinary Shares will be
purchased in accordance with the price and volume conditions set
out in the Commission Delegated Regulation (EU) 2016/1052 of March
8, 2016 supplementing Regulation (EU) No 596/2014 of the European
Parliament and of the Council with regard to regulatory technical
standards for the conditions applicable to buyback programs and
stabilization measures as implemented, retained, amended, extended,
re-enacted or otherwise given effect in the United Kingdom from
January 1, 2021 and as amended or supplemented in the United
Kingdom thereafter. All repurchases by Indivior under the Program
will be "On Exchange" transactions (as such term is defined in the
rules of the London Stock Exchange) and will be "on market" for the
purposes of the Companies Act 2006. Indivior will announce any
market repurchase of Ordinary Shares no later than 7.30 a.m. on the
business day following the calendar day on which the repurchase
occurred.
As the purpose of the Program is to reduce the issued share capital
of Indivior, to the extent permitted by law, all Ordinary Shares
purchased under the Program will be cancelled.
The maximum number of Ordinary Shares that may be repurchased under
the Program is 13,631,504, being the number of Ordinary Shares
Indivior is authorized to repurchase under the terms of the
Authority.
The person responsible for making this announcement is Kathryn
Hudson, Company Secretary.
This announcement does not constitute, or form part of, an offer or
any solicitation of an offer for securities in any
jurisdiction.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat addiction and
serious mental illnesses. Our vision is that all patients around
the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of substance use
disorder (SUD). Indivior is dedicated to transforming SUD from a
global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and co-occurring disorders of SUD, including alcohol use
disorder and cannabis use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more
than 1,000 individuals globally and its portfolio of products is
available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Important Cautionary Note Regarding Forward-Looking
Statements
This news release contains certain statements that are
forward-looking. Forward-looking statements include, among other
things, the amount or value of shares that will be repurchased, the
attractiveness of our shares as an investment, expected future
growth, our ability to execute our business strategy and return
capital to shareholders, our future cash flows, our ability to
reinvest in the business and progress our pipeline and other
statements containing the words "believe", "anticipate", "plan",
"expect", "intend", "estimate", "forecast," "strategy," "target,"
"guidance," "outlook," "potential", "project", "priority," "may",
"will", "should", "would", "could", "can", "outlook," "guidance",
the negatives thereof, and variations thereon and similar
expressions. By their nature, forward-looking statements involve
risks and uncertainties as they relate to events or circumstances
that may or may not occur in the future.
Readers are cautioned not to place undue reliance on any such
forward-looking statements. Actual results may differ materially
from those expressed or implied in such statements because they
relate to future events. Various factors may cause differences
between Indivior's expectations and actual results, including,
among others, the substantial litigation and ongoing investigations
to which we are or may become a party; our reliance on third
parties to manufacture commercial supplies of most of our products,
conduct our clinical trials and at times to collaborate on products
in our pipeline; our ability to comply with legal and regulatory
settlements, healthcare laws and regulations, requirements imposed
by regulatory agencies and payment and reporting obligations under
government pricing programs; risks related to the manufacture and
distribution of our products, some of which are controlled
substances; market acceptance of our products as well as our
ability to commercialize our products and compete with other market
participants; the uncertainties related to the development of new
products, including through acquisitions, and the related
regulatory approval process; our dependence on a small number of
significant customers; our ability to retain key personnel or
attract new personnel; our dependence on third-party payors for the
reimbursement of our products and the increasing focus on pricing
and competition in our industry; unintended side effects caused by
the clinical study or commercial use of our products; our use of
hazardous materials in our manufacturing facilities; our import,
manufacturing and distribution of controlled substances; our
ability to successfully execute acquisitions, partnerships, joint
ventures, dispositions or other strategic acquisitions; our ability
to protect our intellectual property rights and the substantial
cost of litigation or other proceedings related to intellectual
property rights; the risks related to product liability claims or
product recalls; the significant amount of laws and regulations
that we are subject to, including due to the international nature
of our business; macroeconomic trends and other global developments
such as the COVID-19 pandemic; the terms of our debt instruments,
changes in our credit ratings and our ability to service our
indebtedness and other obligations as they come due; changes in
applicable tax rate or tax rules, regulations or interpretations;
and our ability to realize our deferred tax assets; and changes in
our market position, businesses, financial condition, results of
operations or prospects. Additional information concerning these
and other factors can be found in Indivior PLC's filings with the
United States Securities and Exchange Commission ("SEC"), including
Indivior PLC's registration statement on Form 20-F, which was
declared effective by the SEC on June 9, 2023, and Current Reports
on Form 6-K, which may be obtained free of charge at the SEC's
website, http://www.sec.gov, and Indivior PLC's Annual Reports,
which may be obtained free of charge from Indivior PLC's website,
https://www.indivior.com/.
Forward-looking statements speak only as of the date that they are
made and should be regarded solely as our current plans, estimates
and beliefs. Except as required by law, we do not undertake and
specifically decline any obligation to update, republish or revise
forward-looking statements to reflect future events or
circumstances or to reflect the occurrences of unanticipated
events.
Media
Contacts:
US Media:
Cassie France-Kelly
Vice President, Communications
Indivior PLC
Tel: 804-724-0327
UK Media:
Teneo
Tel: +44 207-353-4200
Investors
and Analysts:
Jason Thompson
Vice President, Investor Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor Relations
Indivior PLC
Tel: 804-263-3978
-ends-